AVITA Medical (RCEL) Projected to Post Earnings on Thursday

AVITA Medical (NASDAQ:RCEL - Get Free Report) is anticipated to announce its Q1 2025 earnings results after the market closes on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.39) per share and revenue of $33.15 million for the quarter.

AVITA Medical (NASDAQ:RCEL - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.14). The business had revenue of $18.41 million for the quarter, compared to the consensus estimate of $18.40 million. AVITA Medical had a negative return on equity of 337.91% and a negative net margin of 96.26%. On average, analysts expect AVITA Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AVITA Medical Price Performance

Shares of NASDAQ RCEL traded down $0.23 during trading on Tuesday, hitting $8.98. The company had a trading volume of 103,780 shares, compared to its average volume of 174,387. AVITA Medical has a 52 week low of $6.90 and a 52 week high of $14.16. The business's 50-day moving average is $8.87 and its 200 day moving average is $10.32. The company has a market cap of $237.39 million, a P/E ratio of -3.75 and a beta of 1.74. The company has a debt-to-equity ratio of 9.39, a quick ratio of 2.47 and a current ratio of 2.83.

Insider Buying and Selling at AVITA Medical

In other AVITA Medical news, Director Robert Mcnamara acquired 10,000 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was purchased at an average cost of $10.09 per share, for a total transaction of $100,900.00. Following the transaction, the director now owns 45,749 shares of the company's stock, valued at $461,607.41. The trade was a 27.97 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.82% of the company's stock.

Analyst Upgrades and Downgrades

RCEL has been the subject of several analyst reports. D. Boral Capital reaffirmed a "buy" rating and set a $22.00 target price on shares of AVITA Medical in a report on Thursday, April 10th. Lake Street Capital cut their price objective on AVITA Medical from $20.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.